(2R,4R)-2-hydroxy-4-[(3R,5S,7R,8R,10S,13R,14S,15S,17R)-3,7,15-tris(methoxymethoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (2R,4R)-2-hydroxy-4-[(3R,5S,7R,8R,10S,13R,14S,15S,17R)-3,7,15-tris(methoxymethoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• 化学式: C₃₀H₅₂O₉
• 分子量: 556.7
• InChiKey: WPDLOMBGWBYRGJ-GBEWGWIWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• ROR gamma modulators
  申请人：ETH Zurich

  公开号：EP2781217A1

  公开（公告）日：2014-09-24

  The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, characterized in that at least one of R8, R9, R10 is -ORa; for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.

  本发明涉及式 I 化合物或其药学上可接受的盐、 其特征在于，R8、R9、R10 中至少有一个是-ORa；用于治疗或预防、抑制或改善由 ROR γ 受体介导的疾病，特别是糖尿病和糖尿病相关疾病，尤其是 II 型糖尿病，其生产方法，以及治疗或预防此类疾病的方法。